Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.

ClinicalTrials.gov ID: NCT02465632

Public ClinicalTrials.gov record NCT02465632. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 26, 2026, 12:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) to the Marketed Product BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5% (Valeant Pharmaceuticals, US) in the Treatment of Acne Vulgaris.

Study identification

NCT ID
NCT02465632
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Enrollment
1,100 participants

Conditions and interventions

Conditions

Interventions

  • Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel Drug
  • BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5% Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
12 Years to 40 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2015
Primary completion
Oct 31, 2015
Completion
Nov 30, 2015
Last update posted
Jun 27, 2017

2015

United States locations

U.S. sites
13
U.S. states
6
U.S. cities
12
Facility City State ZIP Site status
Glenmark Investigational Site 13 Anaheim California
Glenmark Investigational Site 6 Long Beach California
Glenmark Investigational Site 15 Los Angeles California
Glenmark Investigational Site12 West Covina California
Glenmark Investigational Site 4 Brandon Florida
Glenmark Investigational Site 1 Miami Florida
Glenmark Investigational Site 8 Miami Florida
Glenmark Investigational Site 9 Miramar Florida
Glenmark Investigational Site 2 St. Petersburg Florida
Glenmark Investigational Site 5 Louisville Kentucky
Glenmark Investigational Site7 Upper Saint Clair Pennsylvania
Glenmark Investigational Site 14 Greenville South Carolina
Glenmark Investigational Site 3 Nashville Tennessee

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02465632, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 27, 2017 · Synced Jun 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02465632 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →